Hair restoration has no shortage of options, from topical minoxidil to oral finasteride to platelet-rich plasma injections. Exosome therapy is the newest name on that list, and searches for it have climbed as clinics add it to their menus. The claims can be loud. The underlying biology is more specific, and more useful to understand, than most marketing copy suggests.

What's actually happening at the follicle

A hair follicle cycles through growth (anagen), regression (catagen), and rest (telogen). Hair loss, whatever its cause, is generally a story of follicles spending more time in telogen and less in anagen, or miniaturising with each cycle until they stop producing a visible hair at all. The cells most implicated in keeping a follicle in its growth phase are dermal papilla cells, a small cluster at the base of the follicle that signals to the surrounding hair matrix.

Exosomes are being studied for their potential to support this signalling environment: promoting angiogenesis (the small blood vessels that feed a follicle), carrying growth factors associated with keratinocyte proliferation, and creating conditions that are more supportive of the anagen phase. This is mechanism-based research, not a guarantee of outcome for any individual, and results are expected to vary by cause of hair loss, follicle miniaturisation stage, and consistency of use.

How scalp exosome treatments are typically delivered

Two delivery approaches are common in clinical and at-home settings:

  • In-clinic protocols, often pairing microneedling with a topical exosome application immediately after, on the reasoning that microchannels improve penetration past the stratum corneum.
  • At-home topical serums, applied directly to a clean, dry scalp on a regular schedule, without microneedling, relying on the formulation's own penetration profile.

Neither approach is intrinsically superior; they suit different patient preferences and different product formulations. A serum designed for daily at-home use, like Hakke's Scalp Care, is formulated differently from a concentrate intended for a single in-clinic session.

Exosomes alongside minoxidil and finasteride

Exosome therapy is generally discussed as a complement to, not a replacement for, established treatments. Minoxidil and finasteride work through well-characterised pharmacological mechanisms with decades of trial data behind them. Exosome research is newer and the evidence base is still developing. Clinics that offer exosome scalp treatments typically position them as an addition to an existing regimen rather than a substitute, and any decision about combining or replacing treatments belongs with a qualified practitioner who knows the patient's history.

What separates a real product from a marketing claim

"Exosome" is an increasingly common word on a label, and the gap between products can be wide. Before recommending or purchasing a scalp exosome product, the same questions apply as for any exosome preparation:

  • Is the exosome count per vial documented? A specific figure, not a vague claim of "millions of exosomes."
  • Is the tissue source disclosed? Umbilical cord (Wharton's jelly), dental pulp, and adipose-derived exosomes carry different signalling profiles, covered in more depth in our comparison of Wharton's jelly and dental pulp.
  • Is the bioactive profile quantified? Concentrations of specific growth factors, typically in pg/mL, rather than a list of ingredient names with no numbers attached.
  • Was it manufactured under GMP conditions? Cleanroom classification and batch documentation indicate a repeatable, controlled process.

Hakke's Exo-D platform, the basis for our Scalp Care formulation, is derived from umbilical-derived stem cells and manufactured in Japan under Class 100 cleanroom conditions, with a documented bioactive profile available on request. You can read the underlying mechanism on our exosome science page.